Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Immediate-release Mucinex lasts about four hours, while extended-release Mucinex lasts up to 12 hours. Adults can take up to 2,400 mg of guaifenesin daily, but children have lower maximum doses. Most ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Unlike other sports, college football's overtime rules offer a unique twist. But with changes in recent years, it's hard to keep up with exactly how OT works in college games. Check out everything you ...

Brian W. Stone does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

We may earn commission from links on this page, but we only recommend products we love. Promise. If you haven’t heard of Hinge, where have you been?! With 30 million users, it’s one of the largest ...

Cancer can spread from where it started (the primary site) to other parts of the body. When cancer cells break away from a tumor, they can travel to other areas of the body through either the ...

Now that Republicans' big tax-and-spending bill has become law, there will be new bureaucratic hurdles for millions of Americans who rely on Medicaid. The new law contains a provision that in most ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...